AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psori…
Drug Manufacturers - General
US, North Chicago [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -3.07 | 74.20 | 76.56 | |
| Graham Fair Price | 13.26 | 8.88 | 7.84 | |
| PEG | -43.78 | 0.87 | -1.54 | |
| Price/Book | 51.18 | 39.94 | 26.42 | |
| Price/Cash Flow | 38.14 | 83.12 | 60.17 | |
| Prices/Earnings | -29.84 | 58.39 | 83.23 | |
| Price/Sales | 35.74 | 25.98 | 19.14 | |
| Price/FCF | 38.14 | 83.12 | 60.17 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -19.78 | 0.67 | 0.83 | |
| Operating Margin | -22.82 | 0.24 | 0.31 | |
| ROA | 50.70 | < 0.005 | < 0.005 | |
| ROE | 0.08 | 0.17 | 115.49 | |
| ROIC | 0.04 | 0.03 | -35.03 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.25 | -0.02 | 998.53 | |
| Dividends QOQ | < 0.005 | 0.05 | 24460.21 | |
| EBIT QOQ | 0.97 | -0.34 | -65.48 | |
| EPS QOQ | -0.54 | 0.67 | 24.80 | |
| FCF QOQ | -0.38 | -0.15 | 59.61 | |
| Revenue QOQ | 0.03 | -0.14 | 418.43 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 154.61 | 93.59 | -39.47 | |
| Days Sales Outstanding (DSO) | 70.20 | 87.36 | 24.44 | |
| Inventory Turnover | 0.58 | 0.96 | 65.20 | |
| Debt/Capitalization | 0.85 | 0.90 | 5.98 | |
| Quick Ratio | 0.63 | 0.72 | 14.12 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 5.87 | 4.53 | -22.85 | |
| Cash | 7.26 | 10.21 | 40.74 | |
| Capex | -0.12 | -0.11 | 6.02 | |
| Free Cash Flow | 2.58 | 2.17 | -15.56 | |
| Revenue | 8.10 | 6.96 | -14.07 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad